{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Syndrome+Coronavirus+2+%28SARS-CoV-2%29&page=11",
    "query": {
      "condition": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 1233,
    "total_pages": 124,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Syndrome+Coronavirus+2+%28SARS-CoV-2%29&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Syndrome+Coronavirus+2+%28SARS-CoV-2%29&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T11:10:54.595Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05780281",
      "title": "VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "VIR-7831",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Remdesivir",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 367,
      "start_date": "2020-12-16",
      "completion_date": "2022-10-04",
      "has_results": true,
      "last_update_posted_date": "2023-12-27",
      "last_synced_at": "2026-10-14T11:10:54.595Z",
      "location_count": 74,
      "location_summary": "Tucson, Arizona • Fresno, California • Loma Linda, California + 50 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05780281"
    },
    {
      "nct_id": "NCT04662671",
      "title": "Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COVID19"
      ],
      "interventions": [
        {
          "name": "RD-X19",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "EmitBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 31,
      "start_date": "2020-11-18",
      "completion_date": "2021-01-30",
      "has_results": true,
      "last_update_posted_date": "2022-09-08",
      "last_synced_at": "2026-10-14T11:10:54.595Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • College Station, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04662671"
    },
    {
      "nct_id": "NCT04639375",
      "title": "Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "Vaccinated with polio vaccine (IPV)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "E-MO Biology Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 300,
      "start_date": "2020-11-15",
      "completion_date": "2022-06-12",
      "has_results": false,
      "last_update_posted_date": "2021-08-27",
      "last_synced_at": "2026-10-14T11:10:54.595Z",
      "location_count": 1,
      "location_summary": "National City, California",
      "locations": [
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04639375"
    },
    {
      "nct_id": "NCT04406064",
      "title": "Viral Specific T-cells for Treatment of COVID-19",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Viral Infection"
      ],
      "interventions": [
        {
          "name": "Viral Specific T-cells (VSTs)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Day and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-01",
      "completion_date": "2025-06",
      "has_results": false,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-10-14T11:10:54.595Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04406064"
    },
    {
      "nct_id": "NCT04365257",
      "title": "Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Prazosin",
          "type": "DRUG"
        },
        {
          "name": "Standard of care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "45 Years to 85 Years"
      },
      "enrollment_count": 5,
      "start_date": "2020-05-13",
      "completion_date": "2022-03-31",
      "has_results": true,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-10-14T11:10:54.595Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04365257"
    },
    {
      "nct_id": "NCT04357977",
      "title": "A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronavirus",
        "COVID"
      ],
      "interventions": [
        {
          "name": "RBA-2",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Kaligia Biosciences, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2020-04",
      "completion_date": "2020-12",
      "has_results": false,
      "last_update_posted_date": "2020-04-22",
      "last_synced_at": "2026-10-14T11:10:54.595Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04357977"
    },
    {
      "nct_id": "NCT05020145",
      "title": "COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immunocompromised",
        "Immunosuppressed",
        "Covid-19",
        "SARS-COV-2",
        "SARS-COV-2 Infection",
        "Breakthrough Infection"
      ],
      "interventions": [
        {
          "name": "BNT162b2 (Tozinameran)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1277747,
      "start_date": "2021-08-25",
      "completion_date": "2021-12-17",
      "has_results": true,
      "last_update_posted_date": "2024-02-12",
      "last_synced_at": "2026-10-14T11:10:54.595Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05020145"
    },
    {
      "nct_id": "NCT04482712",
      "title": "Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)",
        "Respiratory Failure",
        "Sars-CoV2"
      ],
      "interventions": [
        {
          "name": "Rapamycin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-04",
      "completion_date": "2023-01",
      "has_results": false,
      "last_update_posted_date": "2021-06-01",
      "last_synced_at": "2026-10-14T11:10:54.595Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04482712"
    },
    {
      "nct_id": "NCT05463068",
      "title": "Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "NVX-Cov2373",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 911,
      "start_date": "2022-07-11",
      "completion_date": "2022-09-01",
      "has_results": true,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-14T11:10:54.595Z",
      "location_count": 30,
      "location_summary": "Long Beach, California • Sacramento, California • DeLand, Florida + 26 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05463068"
    },
    {
      "nct_id": "NCT04380961",
      "title": "A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Critical Confirmed Coronavirus Disease (COVID)-19"
      ],
      "interventions": [
        {
          "name": "Sirukumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Janssen Pharmaceutica N.V., Belgium",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 212,
      "start_date": "2020-04-24",
      "completion_date": "2021-06-24",
      "has_results": true,
      "last_update_posted_date": "2022-06-21",
      "last_synced_at": "2026-10-14T11:10:54.595Z",
      "location_count": 16,
      "location_summary": "Long Beach, California • Newport Beach, California • Fort Lauderdale, Florida + 13 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04380961"
    }
  ]
}